JavaScript 似乎在您的浏览器中被禁用。 为了您在我们网站能获得最好的体验，建议在浏览器中打开Javascript。

若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。

跳转到图像库的开头

EasySep™人TCR Alpha/Beta去除试剂盒

人TCRαβ+细胞的免疫磁珠去除

只有 %1 左

率先评论此产品

¥9,394.00

产品号 #（选择产品）

产品号 #17847_C

人TCRαβ+细胞的免疫磁珠去除

产品优势

操作简单、快捷，且无需分离柱
分选得到的细胞不带标记

产品组分包括

EasySep™人TCR Alpha/Beta去除试剂盒（产品号#17847）

EasySep™人 TCR Alpha/Beta去除抗体混合物，1 mL
EasySep™ Dextran RapidSpheres™ 磁珠，2 x 1mL

EasySep™人TCR Alpha/Beta去除试剂盒（产品号#100-1660）

EasySep™人TCR Alpha/Beta去除抗体混合物，10 mL
EasySep™ Dextran RapidSpheres™磁珠，2 x 10 mL

立即询价

总览

实验数据

产品说明书及文档

应用领域

总览

使用 EasySep™ 人 TCR Alpha/Beta 去除试剂盒，通过免疫磁珠正选技术，高效去除白细胞单采术样本或扩增的 TCRαβ 基因敲除细胞培养样本中的人 T 细胞受体 α/β 阳性（TCRαβ⁺）细胞。

EasySep™ 技术结合了单克隆抗体的特异性和无柱磁选系统的简便性，在过去 20 多年中被广泛应用于发表的科学研究中。

这种简便、优化的 EasySep™ 操作流程包括使用识别 TCRαβ 的抗体复合物和磁珠对细胞进行标记。标记后的细胞通过 EasySep™磁极，仅需倾倒或移液吸出未标记细胞，即可完成分选操作。TCRαβ⁺ 细胞会保留在管中。整个细胞分选过程最快仅需 13 分钟，所得目的细胞可直接用于流式细胞术、细胞培养或冻存等下游应用。

如需从白细胞单采术样本中大规模去除人 T 细胞受体α/β阳性（TCRαß+）细胞，请参阅大规格（1x10^10细胞）试剂盒（产品号#100-1660）。

了解更多关于 EasySep™ 免疫磁珠技术的工作原理。探索更多可优化您的实验流程的相关产品，包括培养基、添加物、抗体等。

磁极兼容性
• EasySep™磁极（产品号 #18000）
• “The Big Easy” EasySep™磁极（产品号 #18001）
• Easy 50 EasySep™磁极（产品号 #18002）
• Easy 250 EasySep™磁极（产品号 #100-0821）

分类
细胞分选试剂盒

细胞类型
T 细胞

种属
人

样本来源
白细胞单采术样本，其他组织

分选方法
去除

应用
细胞分选

品牌
EasySep

研究领域
免疫，细胞治疗开发

查看更多显示更少

实验数据

The content of TCRab+ cells before and after the cell isolation procedure are 19.1% and 0.1%, respectively.

Figure 1. Typical EasySep™ Human TCR Alpha/Beta Depletion Profile

In the above example, the frequencies of CD3+TCRαß+ cells in the starting and depleted fractions are 19.1% and 0.1%, respectively.

Residual TCRαβ+ Cells Can Be Removed from Expanded TRAC Knockout Cell Populations Using EasySep™ Human TCRαβ Depletion Kit

Figure 2. EasySep™ Human TCRαβ Depletion Kit Can Be Used to Remove Residual TCRαβ+ Cells from Expanded TRAC Knockout Cell Populations After Genome Editing of Human Primary T Cells Using CRISPR-Cas9

Gene-edited TCRαβ knockout T cells were expanded using ImmunoCult™-XF T Cell Expansion Medium (Catalog #10981) for 7 - 10 days, harvested, and resuspended in EasySep™ Buffer (Catalog # 20144) at 5 x 10⁷ cells/mL. Following a 13-minute EasySep™ depletion protocol using EasySep™ Human TCRαβ Depletion Kit (Catalog #17847), ﬂow cytometry was performed to assess the depletion of TCRαβ+ cells. Representative data plots are shown for the frequency of TCRαβ cells in the expanded TRAC knockout cell population before and after EasySep™ depletion.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

产品说明书

Product Name

EasySep™人TCR Alpha/Beta去除试剂盒

Catalog #

17847

Lot #

All

Language

中文

Document Type

Product Information Sheet

Product Name

EasySep™ Human TCR Alpha/Beta Depletion Kit

Catalog #

17847

Lot #

All

Language

English

Document Type

Product Information Sheet - with Easy 250 EasySep™ Magnet

Product Name

EasySep™ Human TCR Alpha/Beta Depletion Kit

Catalog #

100-1660

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

EasySep™ Human TCR Alpha/Beta Depletion Kit

Catalog #

17847

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

EasySep™ Human TCR Alpha/Beta Depletion Kit

Catalog #

17847

Lot #

All

Language

English

Document Type

Safety Data Sheet

Product Name

EasySep™ Human TCR Alpha/Beta Depletion Kit

Catalog #

100-1660

Lot #

All

Language

English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area

Workflow Stages

Workflow Stages for T Cell Research

Cell Sourcing

Cell Isolation

Cell Activation, Expansion, and Differentiation

Cell Characterization

Workflow Stages for T Cell Engineering

Cell Isolation

Cell Activation, Expansion, and Differentiation

Cell Characterization

Cell Cryopreservation

相关材料与文献

WNK1 signalling regulates amino acid transport and mTORC1 activity to sustain acute myeloid leukaemia growth Nature Communications 2025 May

Abstract

The lack of curative therapies for acute myeloid leukaemia (AML) remains an ongoing challenge despite recent advances in the understanding of the molecular basis of the disease. Here we identify the WNK1-OXSR1/STK39 pathway as a previously uncharacterised dependency in AML. We show that genetic depletion and pharmacological inhibition of WNK1 or its downstream phosphorylation targets OXSR1 and STK39 strongly reduce cell proliferation and induce apoptosis in leukaemia cells in vitro and in vivo. Furthermore,we show that the WNK1-OXSR1/STK39 pathway controls mTORC1 signalling via regulating amino acid uptake through a mechanism involving the phosphorylation of amino acid transporters,such as SLC38A2. Our findings underscore an important role of the WNK1-OXSR1/STK39 pathway in regulating amino acid uptake and driving AML progression. With-No-lysine (K) kinase 1 (WNK1) is an atypical serine-threonine kinase that has been implicated in ion transport. Here,the authors show that WNK1 regulates amino acid transport and mTORC1 activity,and that the axis is a vulnerability for acute myeloid leukemia

View publication

Multiplex engineering using microRNA-mediated gene silencing in CAR T cells G. Golinelli et al. Frontiers in Immunology 2025 Aug

Abstract

Multiplex gene-edited chimeric antigen receptor (CAR) T-cell therapies face significant challenges,including potential oncogenic risks associated with double-strand DNA breaks. Targeted microRNAs (miRNAs) may provide a safer,functional,and tunable alternative for gene silencing without the need for DNA editing. As a proof of concept for multiplex gene silencing,we employed an optimized miRNA backbone and gene architecture to silence T-cell receptor (TCR) and major histocompatibility complex class I (MHC-I) in mesothelin-directed CAR (M5CAR) T cells. The efficacy of this approach was compared to CD3ζ and β2-microglobulin (β2M) CRISPR/Cas9 knockout (KO) cells. miRNA-expressing cassettes were incorporated into M5CAR lentiviral vectors,enabling combined gene silencing and CAR expression. Antitumor activity was evaluated using in vitro assays and in vivo pancreatic ductal adenocarcinoma models. Silenced (S) M5CAR T cells retained antitumor functionality comparable to,and in some cases exceeding,that of KO cells. In vivo,S M5CAR T cells achieved tumor control with higher persistence and superior metastasis prevention. In vitro assays demonstrated enhanced resistance to alloreactive natural killer (NK) cells and peripheral blood mononuclear cells (PBMCs). Titratable multiplex gene silencing via targeted miRNAs offers an alternative to gene editing for CAR T cells,with potential advantages in potency,persistence,metastasis prevention,and immune evasion for allogeneic products. This strategy may overcome tumor-induced immunosuppression while avoiding the risks associated with DNA double-strand breaks.

View publication

View All Publications

物种	人
Magnet Compatibility	• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • Easy 50 EasySep™ Magnet (Catalog #18002) • Easy 250 EasySep™ Magnet (Catalog #100-0821)
样本来源	其它细胞系, 白细胞单采术样本
Selection Method	Depletion